Research programme: anticancer protein therapeutics - Advanced Proteome Therapeutics

Drug Profile

Research programme: anticancer protein therapeutics - Advanced Proteome Therapeutics

Alternative Names: Anticancer multimers - Advanced Proteome Therapeutics; Anticancer protein-drug conjugates - Advanced Proteome Therapeutics; APC 101; APC 102; APC 103

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Advanced Proteome Therapeutics
  • Class Drug conjugates; Proteins; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Cell death stimulants; Cell movement activators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer
  • Research Sarcoma

Most Recent Events

  • 18 Jul 2017 Advanced Proteome Therapeutics and National Research Council of Canada enter into a collaboration agreement to develop protein conjugate therapeutics for Cancer
  • 19 Dec 2016 USPTO issues notice of allowance covering APC's technology involving specific proteins that have been attached (linked) to other proteins and exhibit activity against tumour cells
  • 29 Apr 2015 Pharmacodynamics data from a preclinical study in Cancer released by Advanced Proteome Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top